Issue No. 1
By Gianna Iantosca and Stephanie Skouras
Antibody Drug Conjugates (ADCs), if you haven't seen these splashed over Fierce Biotech reports yet as the hottest trend to open up the JP Morgan conference in San Francisco, may we be the first to bring it to your attention. ADCs are biologics that combine both a monoclonal antibody and a cancer therapeutic. Basically, they are "biological missiles for cancer". Pretty crazy picture isn't it? (2),
So why are ADCs taking over every big pharma portfolio and business deal right now? Because ADCs are specific for cancer antigens while not harming healthy cells, allowing them to have a better safety profile (Therefore they may be a safer investment for biotechs. Something biotech desperately needs in this economy.) Which companies are the largest players to watch? Merck signed a $22B deal with Daiichi Sankyo accounting for almost 35% of the total cash spent on ADC deals in 2023!
(1)|
Comments